Overview
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
Eligibility
Inclusion Criteria:
- Age ≥18-≤75 years.
- Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
- Presence of homologous recombination deficiency (HRD).
- No contraindications to chemotherapy, or bevacizumab.
- Signed informed consent to participate in the study.
Exclusion Criteria:
- Presence of another active malignant invasive neoplasm.
- Pregnancy or lactation period.
- Disease progression during treatment.
